CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

Company Overview

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. The product was among the first medicines based on CRISPR gene-editing technology to receive regulatory approval.

Founded in 2013, CRISPR Therapeutics operates internationally, with corporate activities in Switzerland and the United States. In addition to its hemoglobinopathy program, the company is advancing investigational therapies in areas such as cancer, type 1 diabetes and immune-mediated diseases through both internal research and collaborations. Its scientific origins are associated with CRISPR pioneers Emmanuelle Charpentier and Rodger Novak, while Samarth Kulkarni has served as the company’s chief executive officer.

Key Stats

• Today's Range: $51.62 to $53.21
• 50-Day Range: $46.54 to $61.89
• 52-Week Range: $44.12 to $78.48
• Volume: 855,572 shs
• Average Volume: 1.42 million shs
• Market Capitalization: $5.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $68.06
• Consensus Rating: Moderate Buy

CRISPR Therapeutics Stock Analysis - MarketRank™

CRISPR Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 582nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 1 strong buy rating, 10 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

CRISPR Therapeutics has a consensus price target of $68.06, representing about 31.6% upside from its current price of $51.72.

Amount of Analyst Coverage

CRISPR Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($4.47) to ($3.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CRISPR Therapeutics is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CRISPR Therapeutics is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CRISPR Therapeutics has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.48% of the float of CRISPR Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CRISPR Therapeutics has a short interest ratio ("days to cover") of 10.73, which indicates bearish sentiment.

Change versus previous month

Short interest in CRISPR Therapeutics has recently increased by 0.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CRISPR Therapeutics does not currently pay a dividend.

Dividend Growth

CRISPR Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.78

News Sentiment

CRISPR Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for CRISPR Therapeutics this week, compared to 9 articles on an average week.

Search Interest

Only 8 people have searched for CRSP on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

MarketBeat Follows

12 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CRISPR Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.20% of the stock of CRISPR Therapeutics is held by insiders.

Percentage Held by Institutions

69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/13/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRSP
• CIK: 1674416
• Web: www.crisprtx.com
• Phone: (617) 315-4600
• Fax: N/A
• Employees: 393
• Year Founded: 2013

Price Target and Rating

• Average Price Target for CRISPR Therapeutics: $68.06
• High Price Target: $110.00
• Low Price Target: $9.00
• Potential Upside/Downside: +31.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.61
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$581.60 million
• Net Margins: -3,368.72%
• Pretax Margin: -3,346.08%
• Return on Equity: -24.39%
• Return on Assets: -18.25%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 17.85
• Quick Ratio: 17.85

Sales & Book Value

• Annual Sales: $3.51 million
• Price / Sales: 1,424.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $20.17 per share
• Price / Book: 2.56

Miscellaneous

• Outstanding Shares: 96,690,000
• Free Float: 91,665,000
• Market Cap: $5.00 billion
• Optionable: Optionable
• Beta: 1.76